Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.

S H KangY B LeeJeong-Hoon LeeJ Y NamY ChangH ChoJ-J YooY Y ChoE J ChoS J YuM Y KimYun Joon KimS K BaikJ-H Yoon

Published in: Alimentary pharmacology & therapeutics (2017)

In patients without HCC, rifaximin treatment was significantly associated with prolonged overall survival and reduced risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy.

Keyphrases

ejection fraction
newly diagnosed
prognostic factors
early onset
climate change